What We're Reading: Page 253
Industry reads hand-picked by our editors
Sep 11, 2018
-
STAT
Amgen emerges as a multiple myeloma drug player, threatening Bluebird, Celgene
-
The New York Times
How teeth became tusks, and tusks became liabilities
-
Scientific American
RNA expert wins "American Nobel"
Sep 10, 2018
-
The Times
Japan's Takeda family brands Shire deal ‘a disaster’
-
Financial Times
Billionaire Sackler family owns second opioid drugmaker
-
The New York Times
Top cancer researcher fails to disclose corporate financial ties in major research journals
-
The Wall Street Journal
Marijuana-research applications go nowhere at Justice Department
Sep 07, 2018
-
Financial Times
Opioid billionaire granted patent for addiction treatment
-
TechCrunch
23andMe underscores that privacy-loving customers need to opt out of its data deal with GlaxoSmithKline
-
Forbes
Will Trump's pharma shaming bring down drug prices? Not likely, poll says
-
Boston Business Journal
Biotech VCs debate AI, globalization during Boston panel
Sep 06, 2018
-
The Wall Street Journal
Blood-testing firm Theranos to dissolve
-
Scientific American
GMOs are not agriculture's future — biotech is
-
Boston Business Journal
Histogenics to seek FDA approval for cell therapy despite failed study
-
Business Insider
A startup with ties to Bayer has inked a $122 million deal to make lab-grown marijuana — and it's eyeing the pharma industry
-
The Moran Company
PhRMA, hospital war over drug prices heats up
Sep 05, 2018
-
The Wall Street Journal
Big Pharma Catches Up With Biotech
-
Evening Standard
Pfizer says getting ready for Brexit will cost $100M
-
Xconomy
Westlake Bio unveils $320M fund to put Los Angeles on the biotech map
-
The New York Times
Scientists are retooling bacteria to cure disease
Previous
